enVVeno Medical opened higher at $6.62, compared with its previous close of $6.52. In the last trading session, the stock traded between $6.41 and $6.55. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in enVVeno Medical is now worth
$ 2.34
Resulting in a loss of
$ 97.66 (97.66%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+$0.04 (+0.55%)
Day High
$6.55
Day Low
$6.41
Day Open
$6.62
Prev Close
$6.52
Volume
3,912
1W Return
-9.13%
1M Return
-19.57%
3M Return
-38.67%
6M Return
-33.64%
1Y Return
-73.00%
Market Cap ($ Mn)
5
PE Ratio
-
PB Ratio
0.35
PEG Ratio
-
ROE
-57.24%
ROCE
-58.37%
EPS (TTM)
$-5.35
1 Week
-9.13%
1 Month
-19.57%
3 Months
-38.67%
6 Months
-33.64%
9 Months
-29.51%
enVVeno Medical to showcase enVVe system at 38th TCT symposium
enVVeno Medical will present its investigational enVVe System at the 38th annual TCT Scientific Symposium on November 2, 2026. The presentation focuses on a transcatheter replacement venous valve for treating severe deep venous insufficiency. An estimated 3 million people in the U.S. suffer from severe DVI, which currently lacks curative treatment options. CEO Rob Berman will deliver the talk during the Innovation in Endovascular Therapies session at 11:30 am PT.
10 days agoenVVeno Medical to feature enVVe system at Veins 2026 summit
enVVeno Medical presents enVVe System at The VEINS 2026 Summit on October 4, 2026. FDA IDE approval received for TAVVE pivotal trial with enrollment starting Q4 2026. Device targets severe deep venous insufficiency affecting 3 million US patients. Presentation led by Karen B. Garby, MD, Director of Venous Intervention.
1mo agoenVVeno Medical CEO launches 'WTF' video series for investors
enVVeno Medical launches 'WTF Rob Berman' video series for direct investor communication. CEO Rob Berman hosts the series to explain clinical progress without corporate spin. Content covers the enVVe System and the path to the SAVVE pivotal trial. Target market includes 3 million U.S. patients with severe deep venous insufficiency.
1mo agoenVVeno Medical files prospectus to offer securities for up to $100 million
enVVeno Medical filed an SEC prospectus to offer securities. The company seeks to raise up to $100 million through the offering. No additional financial results or operational data were disclosed.
2mo agoenVVeno study shows $32,000 savings per patient for venous valve therapy
enVVeno Medical announced the publication of a peer-reviewed study confirming its venous valve replacement therapy is economically dominant versus standard care. The study projects more than $32,000 in savings per patient and approximately $5.9 billion in annual industry savings with broader adoption, supporting future reimbursement efforts for its enVVe device.
3mo agoenVVeno Medical cuts Q2 net loss by 46% on cost discipline
enVVeno Medical cut its Q2 net loss by 46% to $3.6M, with EPS improving to $(5.37). The company secured FDA IDE approval for its pivotal TAVVE study and holds $21.5M in cash, funding operations through Q3 2027.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in enVVeno Medical is now worth
$ 2.34
Resulting in a loss of
$ 97.66 (97.66%)
Note: Past profits do not guarantee future returns.
